Vicor Technologies, Inc. (OTCBB: VCRT) is a bio-technology company focused on the development and commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i® nonlinear algorithm and software to stratify patients:
- at risk of sudden cardiac death or autonomic nervous system dysfunction, and
- trauma victims in need of immediate lifesaving intervention.
Diagnostics that enable inexpensive, accurate, and early identification of disease states in at-risk populations prior to costly treatments for advanced disease or inaccurate identification are garnering increased attention in the current healthcare debate. These populations are significant, representing:
- 12 million at-risk cardiac patients,
- 23.7 million diabetics, and
- 38 million trauma incidents
Vicor's diagnostics are being developed to address those needs easily, accurately and inexpensively. Vicor has the necessary regulatory approvals and existing CPT codes to market the technology to physicians in early 2010, thus creating a current source of revenue for Vicor.
more…
